Acinetobacter baumannii is one of the most commonly encountered, highly resistant pathogens requiring novel therapeutic interventions.
Acinetobacter baumannii is one of the most common and antibiotic-resistant pathogens in the United States and throughout the world [1] [2] [3] . National surveillance data from [2009] [2010] [2011] [2012] demonstrated that an astonishing 50% of A. baumannii isolates from US intensive care units were extensively drug-resistant (XDR) (ie, resistant to carbapenems and all other antibiotics except colistin or tigecycline)-more than other pathogens, including Pseudomonas aeruginosa (20%) and Klebsiella pneumoniae (10%) [4] . Every year in the United States, these infections cause >10 000 deaths and excess healthcare costs of $390 million; outside the United States they cause >30 000 deaths and excess healthcare costs of $742 million [5, 6] . Moreover, bacteremia and ventilator-associated pneumonia caused by XDR A. baumannii result in >50% mortality rates due to inadequate available therapy [7] [8] [9] [10] [11] . Worse still, in contrast to other resistant bacteria, few antibiotics are in the pipeline to treat XDR A. baumannii [6, 12] . Thus, new strategies to prevent and treat these infections are critically needed.
Recently, we found that A. baumannii virulence is driven by evasion of innate immune clearance, allowing high bacterial burdens to trigger Toll-like receptor 4 (TLR4) via lipopolysaccharide (LPS), which induces sepsis [6, [13] [14] [15] . It has been shown that active immunization with A. baumannii and passive immunization with resultant immune serum both protect mice from otherwise lethal bacteremia and pneumonia infections [16] [17] [18] . Also, an anticapsular monoclonal antibody (mAb) enhanced clearance of A. baumannii from a rat soft tissue wound infection model [19] . We now describe an mAbbased therapy that is highly protective during bloodstream and lung infections, by defining its in vitro and in vivo antibacterial effects, including in combination with a standard anti-A. baumannii antibiotic. Moreover, we demonstrate efficacy with a humanized variant of the mAb. These results support the rapid translation of the mAb as adjunctive therapy for XDR and pandrug-resistant (PDR) A. baumannii infections.
MATERIALS AND METHODS

Generation of Hybridomas
We immunized mice intravenously (IV) with sublethal inocula (<10 6 CFU) of Harbor UCLA Medical Center-1 (HUMC1) strain. Two weeks following the last boost and 3 days before harvesting of spleens for hybridoma fusion, mice were subcutaneously injected with 50 µg antimouse CD40 mAb (clone 5C3, BioLegend) [20] . Hybridoma cell lines were propagated in 96-well, flat-bottom plates in Dulbecco's Modified Eagle's medium (DMEM-20) (Life Technologies Cat. #11965-084) supplemented with 1 mM pyruvate, 10 mM HEPES, 1% penicillin/streptomycin, and 20% FBS; and supernatants were harvested from wells for initial flow cytometry screening to identify antibodies that bound to intact bacteria. Subcloned monoclonal hybridomas were slowly transitioned from DMEM-20 to protein-free hybridoma media (Life Technologies). Antibodies were purified from monoclonal hybridoma supernatants using Pierce Protein G agarose resin (Thermo Fisher Scientific) according to the manufacturer's instructions. Isotype was determined by enzyme-linked immunosorbent assay (ELISA) BD Pharmingen Mouse Immunoglobulin Isotyping ELISA Kit (Thermo Fisher Scientific).
Bacterial Binding by Flow Cytometry
To assess surface binding of antibodies, A. baumannii subcultures were passaged for 3 hours to mid-log-growth, washed 3 times in phosphate-buffered saline (PBS), and then resuspended in PBS supplemented with 0.1% NaN 3 (to prevent contamination in flow cytometer). Hybridoma supernatant or purified material was added to each well, gently mixed on plate vortexer, and incubated for 30 minutes at 37°C. Cells were washed and transferred to 5 mL fluorescence-activated cell sorting tubs in PBS. Flow cytometry was conducted on a CANTO II cytometer (BD) with staining by AF647-conjugated anti-immunoglobulin G (IgG) secondary antibody.
Immunofluorescence
To detect surface binding of A. baumannii by purified C8 mAb, mid-log-growth A. baumannii strains were washed twice, resuspended in PBS, stained with NucBlue Reagent (Life Technologies) for 30 minutes at 37°C, pelleted, and washed again in PBS. Primary antibody, either C8 or isotype control mAb, was added to 100 µL of bacteria to a final concentration of 100 µg/mL and incubated for 30 minutes at 37°C. Bacteria were washed twice and resuspended in AF647-conjugated secondary antibody, goat antimouse IgG (Life Technologies, catalog number A21235) at a final concentration of 2 µg/mL for 20 minutes at 37°C. After washing twice with PBS, bacteria were resuspended in 50 µL PBS and 10 µL drops were placed on slides and mounted with cover slips and nail polish. Images were taken using a Spinning Disc Confocal Microscope (Zeiss AxioImager).
Lung sections were paraffin embedded on slides, then baked at 60°C overnight. Slides were rehydrated and incubated in antigen retrieval solution (Dako Target Retrieval Solution) then blocking buffer (0.1% bovine serum albumin, 0.01% Triton-X, in PBS). The slides were stained overnight at 4°C with A. baumannii immune serum diluted 1:500 in PBS. On the following day, slides were rinsed with PBS and stained for 45 minutes at room temperature with the secondary antibody (American Qualex Goat antimouse IgG H+L Fluorescein A106FZYP) diluted 1:40 in PBS. Slides were rinsed with PBS and mounted with anti-fade mounting media (Vectashield mounting medium for fluorescence with 4' ,6-diamidino-2-phenylindole [DAPI]) and nail polish. Images were captured with a Perkin Elmer Spinning Disc confocal microscope and an Olympus BX61 fluorescence microscope.
Target Identification
To identify the target of the mAb, we made a bacterial surface preparation. In brief, we grew an overnight culture of A. baumannii HUMC1 in trypitic soy broth, centrifuged it at 4000×g for 5 minutes, and extracted capsular polysaccharide with ethylenediaminetetraacetic acid and then phenol, as described previously [19, 21, 22] . Capsule was extracted from cells with water at 40°C for 24 hours, dialyzed, centrifuged at 40 000 rpm for 2 hours, acetic acid added to 1% v/v, and heated for 30 minutes at 100°C. The precipitate was discarded and the solution desalted on a Biogel P10 column. Preparations were analyzed by 1 H nuclear magnetic resonance (NMR), and 2-dimensional NMR spectra were used to determine the nature of the components. Before passing through duplicate 12% acrylamide gels and transferring to Western blot membranes, the bacterial prep was either untreated, treated with sodium periodate to degrade polysaccharides, or treated with proteinase K to degrade polypeptides. The Western blot membranes were bathed in C8 or isotype control mAb.
Surface staining was also tested by flow cytometry against a capsular mutant A. baumannii strain (ATCC 17978 ΔitrA on a background of ATCC 17978), which was a kind gift from MedImmune (Dr Paul Warrener).
In Vitro Complement Susceptibility and Macrophage
Opsonophagocytosis Assays
To measure complement susceptibility, overnight cultures of A. baumannii were subcultured to log phase, washed in PBS, and resuspended to 1 × 10 6 CFU/mL in 3 mL Hank's balanced salt solution (HBSS) containing 50% CD-1 mouse serum (Innovative Research, catalog number IMSCD1-COMPL) that was either complement active or heat inactivated at 57°C for 30 minutes. Tubes were shaken at 200 rpm for 2 hours at 37°C and bacterial density was quantified by serially diluting cultures, plating on tryptic soy agar, and counting CFUs.
To measure opsonophagocytosis, we used RAW 264.7 murine macrophages (ATCC, 5 × 10 5 /well) stimulated with 100 U/mL interferon-γ or human HL-60 cells (ATCC, 5 × 10 5 /well) differentiated into macrophages by incubating for 5 days in the presence of 50 μM phorbol 12-myristate 13-acetate (PMA), as we previously described [23] . Cells adhered to the cover glass overnight in a humidified incubator at 37°C supplemented with 5% CO 2 . Cells were washed 3 times with HBSS and bacteria were added to wells at a ratio of 20:1 (bacteria to macrophages) in the presence (or absence) of 10% CD-1 mouse serum that was either complement active or heat inactivated. Macrophages were washed 3 times with HBSS, fixed with 100% methanol, and stained with Hema-3 according to the manufacturer's protocol (Fisher Scientific). To quantitate bacteria per macrophage, coverslips were imaged on a Zeiss AxioImager microscope.
The viability of macrophages was assayed after incubation with bacteria by vital dye staining using trypan blue dye. Macrophages with a compromised cell membrane will take on the dye and become blue whereas viable macrophages with an intact cell membrane will exclude the dye. Macrophages were set up as above and incubated with bacteria for 1 hour. At that point, macrophages were removed from the cover glass with a cell scraper and 10 μL of the resultant cell suspension was mixed with 10 μL trypan blue stain (Corning). Blue cells were considered dead or nonviable while clear cells were considered live or viable. Viability was reported as percentage viable by dividing the number of live cells by the total number of cells (live and dead) then multiplying by 100.
Mouse Models of Infection
Male C3HeB/Fe mice (Jackson Labs) between the ages of 7-10 weeks were used for all experiments, as we have previously described for A. baumannii infection [13, 14, 24] . For the bloodstream infection model, mice were infected IV via the tail vein with designated inocula of A. baumannii isolates. An oropharyngeal model of aspiration pneumonia that recapitulates hospital-or ventilator-associated pneumonia (relevant to intensive care unit populations) was used. In brief, mice were sedated with isoflurane and hung by their maxillary incisors; their tongues were held to prevent swallowing, and 50 μL bacterial inocula was placed in the trachea to allow inoculation of the bacteria into the lungs by reflexive aspiration.
All animal work was conducted following approval by the Institutional Animal Care and Use Committee (IACUC) at the University of Southern California, in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (IACUC protocol number 20208).
Humanization of the mAb
Our mAb was humanized by STC Biologics using their well-established methodology. In brief, mAb C8 heavy-and lightchain variable regions were identified by reverse-transcription polymerase chain reaction using the Novagen mouse Ig degenerate primer set per the manufacturer's instructions. Light-and heavy-chain variable regions were aligned with the murine germ line sequences from which they were derived and their human analogues. From these alignments, it was noted that the C8 light-chain variable region is a hybrid of the murine germ line sequences IGKV1-110, IGKV1-117, and IGKJ5. Fortunately, most of the light chain has a natural human homolog IGKV2-30. The human IGKJ4 sequence was chosen for the CDR3 region because it conserves the L98 position in the CDR. 91C8 heavy chain sequence was derived from the murine germ line sequences IGVH1-37, IGVH1-20, and IGHJ3. 91C8 murine heavy chain sequence is most similar to human IGHV1-3*01 and a subset of human amino acids chosen using the TabHu online humanization tool (University of Rome) were substituted. Humanized variable regions were electronically grafted to human IgG1 heavy and light constant regions and synthesized in mammalian expression vectors at GenScript.
Statistical Analysis
Survival was compared by the nonparametric log-rank test. Surface staining and bacterial killing were compared with the Wilcoxon rank-sum test for unpaired comparisons. All statistics were run using KyPlot software. Differences were considered significant if the P value was <.05.
RESULTS
Generation and Characterization of an Anti-A. baumannii mAb
We generated C8, an IgG1-κ mAb, by immunizing mice with viable HUMC1, which is an XDR, hypervirulent, clinical blood and lung isolate of A. baumannii [13, 25] . C8 bound to the surface of HUMC1 at very low (ng/mL) concentrations ( Figure 1A ). Surface binding by flow cytometry substantially above background was observed in 57 of 95 (60%) A. baumannii strains tested, which were obtained from widely divergent geographical and clinical sources (Supplementary Table 1 ). Saturated binding of C8 to the surface of HUMC1 was confirmed by immunofluorescence in a pattern consistent with bacterial capsule ( Figure 1B ).
To further characterize the target of C8, we isolated the carbohydrate surface of A. baumannii [26] . Treatment of the carbohydrates with proteinase K (to degrade polypeptides) did not alter C8 binding to the target by Western blot, but the pattern was entirely ablated by periodate treatment, indicating a carbohydrate rather than a protein target; again, consistent with a capsular epitope. The surface extract to which the mAb bound was evaluated by NMR to define its contents. The material consisted of 1-4, 1-6, and 1-3 linkages of β-d-n-acetylglucosamine, α-d-galactose, and β-d-n-acetylgalactosamine, consistent with A. baumannii capsular carbohydrate [19, 21, 27] .
Finally, we used flow cytometry to assess the binding of C8 to an A. baumannii capsule-disruptant strain, ATCC 17978 ΔitrA, compared to its isogenic parent strain. ATCC 17978 ΔitrA is a capsule polysaccharide-deficient disruptant of ATCC 17978 [28] . While C8 bound to the parent strain (ATCC 17978) with great affinity, C8 bound the capsule disruptant strain (ATCC 17978 ΔitrA) no better than isotype control mAb ( Figure 1E ). Thus, concordant with the diffuse binding pattern seen on immunofluorescence, the target of C8 is capsular polysaccharide.
C8 Opsonized A. baumannii for Increased Macrophage Uptake In Vitro
HUMC1 has been established as a hypervirulent A. baumannii strain as a result of its ability to evade innate immune effector-mediated clearance from the blood within the first hour of a bloodstream infection [14] . Clearance was primarily effected Figure 1 . Surface binding of Acinetobacter baumannii by purified C8 monoclonal antibody (mAb). A, The A. baumannii HUMC1 bacteria grown to log phase were stained with various concentrations of purified C8 (primary antibody), followed by fluorophore-conjugated anti-mouse IgG heavy and light chain (secondary antibody) to assess C8 binding by flow cytometry. Binding of mouse polyclonal immune serum was used as a positive control. B, Confocal immunofluorescence microscopy confirmed diffuse surface binding of C8 mAb (AlexaFluor488, green) to 4',6-diamidino-2-phenylindole-stained (blue) A. baumannii HUMC1. C, Immunogold electron microscopy 40 000× magnification) demonstrates C8 binding to the capsule on A. baumannii HUMC1 (arrows). D, Western blot of surface preparations from A. baumannii, including preparations treated with proteinase K or periodate to degrade protein or carbohydrates, respectively. The blots were stained with C8 or isotype control mAb. E, A. baumannii ATCC 17978 and ATCC 17978 ΔitrA bacteria grown to log phase were stained with various concentrations of purified C8 (primary antibody), followed by fluorophore-conjugated anti-mouse IgG heavy and light chain (secondary antibody) to assess C8 binding by flow cytometry. Binding of mouse polyclonal immune serum was used as a positive control as it is capable of binding noncarbohydrate epitopes.
by macrophages in the reticuloendothelial system with secondary, but additive, effects of neutrophils and complement [14] . We therefore sought to determine the impact of C8 on innate effector mechanisms that can target A. baumannii. Coincubation with C8 did not reduce the density of A. baumannii HUMC1 in the presence of either heat-inactivated (HI) or complement-active CD-1 mouse serum (Supplementary Figure 1) . However, addition of C8 markedly increased macrophage uptake of the hypervirulent XDR A. baumannii strain HUMC1 (Figure 2A and 2C). Macrophage uptake of the hypovirulent A. baumannii strain ATCC 17978, which is inherently efficiently phagocytosed, also increased in the presence of mAb C8 ( Figure 2B ). Although it has been published that A. baumannii can induce apoptosis upon localization of the bacterial surface protein Omp38 to the mitochondria [29] , we confirmed through vital dye staining that most macrophages (>85%) are alive after a 1-hour incubation with A. baumannii and that the addition of mAb to increase phagocytosis had no effect on macrophage survival. Heat-Inactivated Serum
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Complement-Activate Serum Figure 2 . C8 monoclonal antibody (mAb) opsonizes bacteria for uptake by macrophages. A, In contrast, the C8 mAb markedly improved RAW 264.7 macrophage uptake of Acinetobacter baumannii. The A. baumannii HUMC1 log-phase bacteria were incubated with interferon-γ-stimulated RAW 264.7 macrophages for 1 h in Hank's balanced salt solution supplemented with complement-active or heat-inactivated fetal bovine serum (HI-FBS). C8 mAb was added at a final concentration of 5 µg/mL. The C8 mAb enhances phagocytosis of A. baumannii in the presence or absence of complement, but enhancement was greatest with complement. *P < .05 compared to HI-FBS only and FBS-only groups. B, Hypovirulent A. baumannii ATCC 17978 is inherently efficiently phagocytosed by macrophages, but the addition of 5 μg/mL mAb C8 still enhanced phagocytosis. C, Micrographs stained with Hema-3 stain demonstrate the increased phagocytosis of macrophage upon addition of C8 mAb. Median and interquartile ranges are shown.
In Vivo Treatment of Mice With C8 Protected Against Lethal A. baumannii
Bloodstream Infection
When mice were infected IV with a lethal inoculum of hypervirulent A. baumannii HUMC1 and immediately treated with different concentrations of C8 or isotype control mAb, C8 was 100% protective against infection at both a low and high dose ( Figure 3A) . When we repeated the experiment with lower titers of mAb, we confirmed that an extremely low 1-time dose of 5 μg (0.167 mg/kg) was completely protective against IV infection and a dose of only 0.5 μg (0.0167 mg/kg) significantly improved survival ( Figure 3B) .
We sought to determine the impact of delaying treatment on outcome from infection. We administered 50 μg (1.67 mg/kg) of C8 intraperitoneally (which results in further delayed uptake into blood compared to IV administration) after IV infection. Mice were rescued from lethal infection when treated intraperitoneally (IP) at 30 minutes postinfection but not 3 hours postinfection ( Figure 3C ).
As clinical treatment of A. baumannii infections using antibody therapy will likely occur in conjunction with antibiotic treatment, we assessed the efficacy of administering mAb treatment in combination with colistin, at 1 hour postinfection ( Figure 3D ). Delayed monotherapy with C8 once again significantly improved survival compared to isotype control mAb, but still resulted in most mice dying, whereas delayed monotherapy with colistin was completely ineffective. In contrast, 1 hour delayed combination therapy was markedly synergistic, resulting in virtually complete protection (90% survival) against lethal bloodstream infection. Of note, we tested the minimum inhibitory concentration (MIC) of colistin against HUMC1 alone and in the presence of C8 at 0.1, 1, or 10 µg/mL; the MIC was identical in all 4 conditions: 2 µg/mL.
C8 Reduced Bacterial Burden and Precluded Sepsis Syndrome
To determine the mechanism of protection in vivo, we studied the impact of mAb C8 on bacterial density and sepsis syndrome in mice challenged with A. baumannii. Mice were infected IV via the tail vein with HUMC1 and then treated IV with C8 or isotype control mAb. Figure 4 . C8 monoclonal antibody lowered bacterial density and ameliorated the sepsis response to intravenous (IV) Acinetobacter baumannii infection. Mice (n = 5 per group) were infected IV with 1.5 × 10 7 A. baumannii HUMC1 and treated IV with 5 μg isotype control or C8. A, Mice were euthanized and blood was obtained by cardiac puncture at 0 (baseline), 2, and 22 h postinfection; colony-forming units were determined by diluting and plating on agar plates and counting. B, Blood plasma was assessed for cytokine levels at the same time-points in infected and treated mice by Luminex assay. C, Biomarkers of sepsis were assessed in mice by analyzing blood samples to determine indicators of sepsis, renal failure, hypoglycemia, and metabolic acidosis that develop in infected control mice. Control mice developed progressive septic shock between 2 and 24 h, while C8-treated mice maintained baseline physiology. *P < .05 vs control. Median and interquartile ranges are shown. Abbreviations: BUN, blood urea nitrogen; CFU, colony-forming units; IV, intravenous; TNF, tumor necrosis factor. had 1000-fold lower blood bacterial density than mice treated with isotype control mAb ( Figure 4A ). Bacterial density in the blood of C8-treated mice continued to decline during the ensuing 20 hours, while control mice displayed increasing bacterial burden before succumbing to infection. Proinflammatory (interleukin [IL] 1β, IL-6, tumor necrosis factor [TNF]) and anti-inflammatory (IL-10) cytokines were also dramatically reduced in C8-treated mice, correlating with the reduced bacterial load ( Figure 4B ). By 2 hours postinfection, TNF and IL-6 were highly elevated in control mice but were significantly reduced in C8-treated mice. By 22 hours postinfection, IL-1β, IL-6, IL-10, and TNF were present at high levels in control mice but were near baseline in C8-treated mice ( Figure 4B ).
Biomarkers that are elevated during sepsis were congruent with raised cytokine and blood bacterial density: infected control mice developed severe metabolic acidosis with high base deficit, severe renal failure based on elevated blood urea nitrogen (BUN), hypoglycemia, and low blood pH-all consistent with septic shock syndrome ( Figure 4C ). By comparison, at 22 hours postinfection C8-treated mice had normal blood glucose as well as baseline BUN levels, base deficit, and blood pH.
In Vivo Treatment of Mice With C8 Protects Against Lethal A. baumannii
Lung Infection
We further tested the efficacy of C8 in another clinically relevant in vivo model of infection: an aspiration pneumonia model consistent with the most common clinical presentation of A. baumannii infection. C8 was nearly fully protective against aspiration pneumonia in mice at a dose of 5 µg per mouse delivered IV ( Figure 5A ) and fully protective at 50 µg per mouse delivered IP, whether administered immediately or even 4 hours postinfection ( Figure 5B ). At 24 hours postinfection, bacterial burden in both the lungs and the blood decreased significantly (3-log and 7-log reductions, respectively) in mice treated with 50 µg C8 IP compared to control mice ( Figure 5C and 5D) . When examined by microscopy, bacterial burden in the lungs was clearly greater in the control mice than the C8-treated mice ( Figure 5E ). By 2 hours postinfection, control-mouse lungs began to demonstrate thickened intralobular septa and early alveolar consolidation. At 24 hours . Three mice per group were euthanized at 2 h and 24 h postinfection, and lung homogenates (C) and blood (D) were diluted and plated on agar to determine bacterial burdens; brackets indicate range. E, Hematoxylin and eosin-stained lungs from the same mice demonstrated onset of pulmonary consolidation (white asterisks, ×100 magnification) and thickened intralobular septa (black arrows, ×400 magnification) by 2 h postinfection, which transformed into severe alveolar hemorrhagic consolidation by 24 h postinfection in the control mice. In contrast, C8-treated mice maintained normal lung architecture. Fluorescence microscopy of lung tissue (4',6-diamidino-2-phenylindole, blue) infected with A. baumannii (AlexaFluor488, green) from the same mice confirmed that C8-treated mice were better able to clear bacteria than the control mice. *P < .05 vs control.
postinfection, control-mouse lungs demonstrated severe hemorrhagic alveolar consolidation, while lungs from C8-treated mice appeared normal. Fluorescence microscopy of lung tissue (DAPI, blue) from mice infected with A. baumannii HUMC1 (AlexaFluor488, green) confirmed C8-treated mice were better able to clear bacteria than the control mice.
Serially Passaging Bacteria With C8 Did Not Diminish mAb Binding
To determine whether escape mutants would develop under selective pressure of C8 mAb, we serially passaged A. baumannii HUMC1 in the presence of C8 or isotype control mAb, with complement-active CD-1 mouse serum. Serial passaging did not result in loss of C8 epitope, as C8 bound passaged bacteria as well as immune serum by flow cytometry ( Figure 6A ). Furthermore, analysis of the carbohydrate linkages in the capsule revealed that capsular composition did not change after passaging. However, macrophage phagocytosis of strains passaged with either isotype control or C8 was significantly enhanced after passaging, even when C8 was not present in the wells with the macrophages ( Figure 6B ). As the phenotype occurred even with passaging in isotype control, the phenotype was not attributable to passaging in C8, and was likely due to passaging in serum. Of note, the increase in uptake by macrophages was still further enhanced when C8 was present during the opsonophagocytosis assay. Thus, passaging in serum with or without C8 did not lead to escape mutants that could avoid C8-mediated increase in opsonophagocytosis. Finally, this enhanced uptake by macrophages post-passaging resulted in a complete loss of virulence in mice ( Figure 6C ).
Humanized C8 mAb Retained In Vitro and In Vivo Efficacy
Humanization of mAb C8 was completed by STC Biologics (Cambridge, Massachusetts). Bacterial surface binding was preserved in the fully humanized mAb clone when assayed by flow cytometry ( Figure 7A ). The humanized mAb demonstrated reduced ability to enhance murine macrophage phagocytosis of A. baumannii compared to murine antibody ( Figure 7B and 7C), but demonstrated markedly superior enhancement of phagocytosis by human macrophages than the murine mAb ( Figure 7D ). The humanized mAb was also tested for in vivo efficacy in the IV infection model and found to be protective at a 50-μg dose ( Figure 7E ). . B, When bacteria were passaged in serum with or without C8, no loss of C8 binding occurred by flow cytometry, and macrophages were able to phagocytose significantly more bacteria than the parent strain. *P < .05. C, The passaged bacteria lost virulence in mice. *P < .05 vs parental strain. **P < .05 for macrophage uptake in the presence (+C8) vs absence (-C8) of C8 during the opsonophagocytosis assay. Median and interquartile ranges are shown. Abbreviation: IV, intravenous.
[6]. Identification of alternative therapeutic approaches is of substantial importance, as new antibacterial therapies for these lethal infections will not likely be available in the coming decade. Here we identified C8, an mAb that binds to the surface of A. baumannii and is highly effective at treating bacteremia and pneumonia caused by hypervirulent and XDR clinical isolates, even in the setting of delayed therapy. Of great translational importance is the synergy observed when mice were given delayed treatment with mAb plus colistin combination therapy, the latter of which is the standard antibiotic treatment for XDR A. baumannii infections. This finding enables a viable clinical development pathway, as any clinical trial of mAb therapy will occur in the setting of background antibiotic regimens, which could mask mAb efficacy if synergy does not occur between the mAb and antibiotic. We have previously reported that mice infected IV with hypervirulent A. baumannii succumb to lethal, LPS-TLR4-driven septic shock [13, 14] . Reaching a bacterial density of ≥10 7 colony-forming units (CFU)/mL in the blood by 1 hour postinfection invariably led to subsequent onset of uniformly fatal septic shock, with severe metabolic acidosis. In contrast, mice that were able to reduce bacterial density in the blood within the first hour, subsequently cleared the infection, and survived. Our current results confirm the importance of that early postinfection window where administration of the mAb within an hour after infection enabled the mice to clear the bacteria, avoid . Humanized C8 monoclonal antibody (mAb) retained in vitro and in vivo efficacy against Acinetobacter baumannii. A, Humanized C8 mAb bound well to the surface of A. baumannii. B and C, Humanized C8 mAb opsonized bacteria for murine macrophage phagocytosis less avidly than murine C8 mAb. *P < .05 compared to isotype control. **P < .05 compared to isotype control and humanized C8. D, In contrast, humanized C8 mAb (5 µg/mL) opsonized bacteria for human macrophage phagocytosis significantly better than murine C8 mAb. *P < .05 compared to isotype control. **P < .05 compared to isotype control and murine C8. E, Humanized C8 protected mice against intravenous (IV) infection at 50 μg/mouse. *P < .05. Median and interquartile ranges are shown.
onset of septic shock, and survive the infection. Administration of C8 intraperitoneally at 3 hours post-IV infection, causing further delay to achieve peak plasma levels, was too late as the sepsis cascade had already been triggered, so mice progressed to septic shock and renal failure. The models we tested are similar to those previously used to validate efficacy of an antipseudomonal antibody that is in clinical trials [30] . Such preclinical models of gram-negative bacterial infections reflect an accelerated disease course. Nevertheless, they are very predictive of clinical efficacy of therapeutics in patients in most cases. We emphasize that even effective antibacterial therapy administered an hour or more after infection could not rescue the mice in our model, whereas modest efficacy of mAb alone was preserved at an hour after infection and combining mAb with antibiotic was almost completely protective. Furthermore, in the lung infection model, pneumonia did not appear histologically until 2 hours postinfection, affording a greater window of opportunity to initiate delayed therapy. Indeed, we found that C8 mAb therapy administered IP 4 hours postinfection was fully protective. Future clinical trials will use rapid diagnostic technology to support timely identification of the pathogen. Trials of this nature can be conducted as laid out in a societal white paper [31] , which was the basis for the subsequent US Food and Drug Administration Center for Drug Evaluation and Research guidance on the conduct of superiority trials targeting highly resistant pathogens.
One concern about developing an mAb-based therapy is that it could lead to selection of escape mutants, akin to emergence of antibacterial resistance under antibiotic selective pressure, or to the strain replacement seen in patients given active vaccines. This concept has not been well validated or explored for antibacterial mAbs. Of note was our finding that serially passaging A. baumannii in the presence of C8 did not result in an escape mutant with decreased C8 binding or opsonophagocytic enhancement of macrophage uptake. However, passaging resulted in increased macrophage phagocytosis even in the absence of C8, and this phenotype resulted in a loss of in vivo virulence. Finally, humanization of the mAb resulted in retention of surface binding, opsonophagocytic enhancement, and in vivo efficacy, supporting rapid translational development of C8 as an adjunctive therapy to treat A. baumannii infections.
Future work will seek to further translate the mAb into a clinical tool. This work includes assessing the mAb for toxicity by screening against human tissue samples, generating a stably transfected master cell-bank clone, and establishing GMP production. Because C8 is able to bind 60% of A. baumannii strains tested, multiple antibodies may be required to achieve sufficient strain coverage (~90%) for empiric therapy.
In summary, we report an mAb that is highly protective in bloodstream and lung models of A. baumannii infection, including against a hypervirulent, XDR clinical isolate. The mAb enhanced bacterial clearance, prevented progression to septic shock, and worked synergistically when combined with antibiotic therapy. Furthermore, mAb efficacy was retained after humanization. These results support translational development of a novel mAb-based therapeutic approach to A. baumannii infections, particularly as therapy against XDR/ PDR strains for which antibacterial regimens are currently inadequate.
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